Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Argent Biopharma ( (AU:RGT) ) has provided an announcement.
Argent Biopharma Limited has applied for quotation of 20,000,000 new ordinary fully paid shares on the ASX, with an issue date of April 10, 2026. The application, lodged as an Appendix 2A, formalizes the company’s request for these securities to commence trading and signals an expansion of its listed capital base, which may support future funding or strategic initiatives.
The move increases Argent Biopharma’s number of quoted securities and could enhance liquidity for existing and new investors in the stock. While the release does not specify the underlying transaction or use of proceeds, the enlarged capital structure potentially strengthens the company’s financial flexibility within the biopharmaceutical market.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
More about Argent Biopharma
Argent Biopharma Limited is an Australian-listed biotechnology company trading on the ASX under the code RGT. The company operates in the biopharmaceutical sector, though this announcement provides no additional detail on its specific products, services, or therapeutic focus.
Average Trading Volume: 195,442
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.03M
See more insights into RGT stock on TipRanks’ Stock Analysis page.